Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pain Drug Development Becomes Personalized

This article was originally published in RPM Report

Executive Summary

Advances in pain neurobiology point to the promise of more specific drugs with fewer side effects, yet the field continues to show few successes. Nevertheless, fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers.

You may also be interested in...



Afferent Pharmaceuticals Inc.

In drug development, the tiniest of targets sometimes prove windows of huge opportunity. For chronic pain start-up Afferent Pharmaceuticals Inc., a single receptor subfamily may hold the key to unlocking novel treatments for that tough-to-alleviate disorder and a remarkable number of other diseases.

Adynxx Inc.

Adynxx Inc.’s first clinical candidate is a one-time treatment to keep acute postoperative pain out of the brain. The same pain pathway-blocking strategy underlies a therapeutic pipeline the company plans to develop for the huge need for a better solution for the five million patients in the US who are treated for chronic pain annually.

Katama Pharmaceuticals Inc.

Katama Pharmaceuticals Inc. was built around tolperisone, a generic, oral small molecule muscle relaxant manufactured and sold in Europe for the treatment of muscular pain and neuromuscular spasms. Katama aims to launch its version in the US, initially for treating acute lower back pain.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS081099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel